NAD+ Precursors Compared: NMN vs NR vs Niacin vs Tryptophan (2026)

Your body can build NAD+ (nicotinamide adenine dinucleotide -- the coenzyme required for 500+ cellular reactions including energy production and DNA repair) from four different starting materials, through four different biochemical routes. The supplement industry wants you to believe there's exactly one correct choice. The science is more nuanced than that.

NMN, NR, niacin, and tryptophan all end up producing the same molecule. But how they get there -- the pathway they use, the tissues they reach, the side effects they cause, and the clinical data behind them -- differs enormously.

This is the complete comparison. No product recommendations. Just the biochemistry, the human trial data, and what it actually means for choosing a precursor.

TL;DR

• Your body makes NAD+ through four distinct pathways, each using a different precursor: NMN (salvage pathway), NR (NRK pathway), niacin (Preiss-Handler pathway), and tryptophan (de novo pathway)
• NMN and NR produce equivalent NAD+ elevation in the first head-to-head human trial (Cuenoud et al. 2025, Nature Metabolism)
• Niacin is the cheapest and most proven precursor but causes flushing (intense skin reddening and heat) in most people at effective doses
• Tryptophan is wildly inefficient -- you need 60mg of tryptophan to make just 1mg of NAD+
• NMN has the most dose-optimization data (600mg optimal, Yi et al. 2023) and is patent-free; NR is patent-restricted to a single supplier
• Emerging research suggests different precursors may be optimal for different tissues -- the "best" precursor may depend on where you need NAD+ most

The Four NAD+ Biosynthesis Pathways

Before comparing precursors, you need to understand that NAD+ isn't built one way. Your body has four distinct manufacturing routes, each feeding into NAD+ from a different entry point. Think of it as four on-ramps to the same highway.

1. The Salvage Pathway (NMN) NAM (nicotinamide, a form of vitamin B3) -> NMN -> NAD+. This is your body's primary recycling system. When sirtuins (a family of seven NAD+-dependent enzymes that regulate aging, metabolism, and cellular repair) and PARPs (poly-ADP-ribose polymerases -- DNA repair enzymes that consume NAD+ to fix damaged DNA) use NAD+, they release nicotinamide as a byproduct. The enzyme NAMPT (nicotinamide phosphoribosyltransferase -- the rate-limiting enzyme in NAD+ recycling) converts it back to NMN, and then NMNAT enzymes (nicotinamide mononucleotide adenylyltransferases) convert NMN to NAD+. Supplemental NMN enters here, skipping the NAMPT bottleneck.

2. The NRK Pathway (NR) NR -> NMN -> NAD+. Nicotinamide riboside is phosphorylated by NRK enzymes (nicotinamide riboside kinases -- enzymes that add a phosphate group to NR, converting it to NMN) into NMN, which then follows the same final step as the salvage pathway. NR requires two enzymatic steps to reach NAD+; NMN requires one.

3. The Preiss-Handler Pathway (Niacin) NA (nicotinic acid) -> NaMN (nicotinic acid mononucleotide) -> NaAD (nicotinic acid adenine dinucleotide) -> NAD+. This is a three-step process involving NAPRT, NMNAT, and NAD synthetase enzymes. It's the pathway used by niacin (nicotinic acid) and, importantly, by the nicotinic acid that gut bacteria produce when they metabolize NMN and NR.

4. The De Novo Pathway (Tryptophan) Tryptophan -> kynurenine -> ... -> quinolinic acid -> NaMN -> NaAD -> NAD+. This is an eight-step pathway that starts from the amino acid tryptophan and winds through the kynurenine pathway (a multi-step metabolic route that converts tryptophan into NAD+ precursors, among other products) before merging with the Preiss-Handler pathway at NaMN. It is the most complex and least efficient route to NAD+.

All four pathways converge on the same final product. The differences lie in efficiency, side effects, tissue specificity, and how much clinical data supports each route.

Key Takeaway: Your body has four pathways to make NAD+: the salvage pathway (NMN/NR), the Preiss-Handler pathway (niacin), the de novo pathway (tryptophan), and direct NMN transport (SLC12A8). Understanding which pathway each precursor feeds explains their different efficiencies, side effect profiles, and optimal use cases.

NMN Deep Dive

What It Is

NMN (nicotinamide mononucleotide) is a nucleotide (a molecule consisting of a nitrogenous base, a sugar, and a phosphate group) naturally found in trace amounts in broccoli, avocado, edamame, and cabbage. It sits one enzymatic step away from NAD+ in the salvage pathway. For a full overview, see What Is NMN? The Complete Guide.

How It Enters Cells

In 2019, Grozio et al. (Nature Metabolism) identified a dedicated NMN transporter called SLC12A8 in the gut lining. This transporter is upregulated (increased in activity) when cellular NAD+ levels are low -- meaning your body actively pulls in more NMN when it needs it most.

However, the Cuenoud 2025 study revealed a critical nuance: a significant fraction of orally consumed NMN is converted by gut bacteria into nicotinic acid (NA) before reaching systemic circulation. That NA then enters the Preiss-Handler pathway to produce NAD+ in the liver. So NMN works through two mechanisms: direct cellular uptake via SLC12A8 (primarily in the gut) and indirect gut microbiome-mediated conversion to NA (for systemic NAD+ elevation).

This has implications for gut health and NAD+.

Clinical Evidence

NMN has the most robust dose-optimization data of any NAD+ precursor:

• Yi et al. 2023 (GeroScience, n=80, RCT): Tested 300mg, 600mg, and 900mg daily in healthy middle-aged adults. 600mg was optimal -- it produced significant NAD+ elevation, improved walking endurance (6-minute walk test), and improved SF-36 health scores. The 900mg dose showed diminishing returns, not a proportional benefit increase. PubMed
• Cuenoud et al. 2025 (Nature Metabolism): Head-to-head comparison of NMN, NR, and nicotinamide. NMN approximately doubled circulating NAD+ over 14 days. Confirmed the gut microbiome-mediated mechanism for systemic NAD+ elevation. PubMed
• Liao et al. 2021 (Journal of International Medical Research, n=48): 250mg NMN daily for 90 days improved aerobic capacity during exercise training in healthy adults.
• Kim et al. 2022 (GeroScience, n=108): NMN supplementation improved sleep quality, reduced drowsiness, and improved lower limb physical function in older adults.
• Katayoshi et al. 2023 (Nutrients, n=11): Single-dose NMN study confirmed acute NAD+ elevation in whole blood within hours of ingestion.

Optimal Dose

600mg/day, based on the Yi et al. 2023 dose-response trial. This is the only NAD+ precursor with a proper multi-arm dose-response RCT establishing an optimum.

Side Effects

NMN is well-tolerated in human trials at doses up to 1,200mg/day. No serious adverse events have been reported in published RCTs. Minor reported effects include mild gastrointestinal discomfort in some participants, typically resolving within the first week.

Patent Status

NMN is not patent-restricted. Multiple manufacturers worldwide produce it, including pharmaceutical-grade suppliers with published stability and purity data. This open competitive market keeps prices lower and gives supplement brands freedom to source from multiple suppliers.

Regulatory Status

As of September 2025, NMN is recognized by the FDA as a lawful dietary supplement. Multiple New Dietary Ingredient Notifications (NDINs) have been filed and accepted. This ended a period of regulatory uncertainty following a brief period in which the FDA considered classifying NMN as an investigational drug.

NR Deep Dive

What It Is

NR (nicotinamide riboside) is a form of vitamin B3 discovered in milk and found in trace amounts in yeast-containing foods. It differs structurally from NMN by lacking a phosphate group -- NR is a nucleoside (base + sugar), while NMN is a nucleotide (base + sugar + phosphate).

For a detailed head-to-head breakdown of NMN and NR specifically, see NMN vs NR: Which NAD+ Precursor Should You Take?.

How It Enters Cells

NR enters cells via equilibrative nucleoside transporters (ENTs -- a family of membrane proteins that shuttle nucleosides into and out of cells). Once inside, it is phosphorylated by NRK1 or NRK2 enzymes to become NMN, which is then converted to NAD+ by NMNAT enzymes. This is a two-step conversion: NR -> NMN -> NAD+.

Like NMN, a significant portion of orally consumed NR is metabolized by gut bacteria before systemic absorption. The Cuenoud 2025 study showed this gut-mediated conversion is the dominant route for systemic NAD+ elevation from NR as well.

Clinical Evidence

NR has a substantial body of human research, though it is notable that much of it was funded by the patent holder:

• Cuenoud et al. 2025 (Nature Metabolism): Head-to-head with NMN -- equivalent NAD+ elevation at matched doses. NR also increased gut production of SCFAs (short-chain fatty acids -- beneficial metabolites produced by gut bacteria that support gut barrier function and reduce inflammation), a secondary finding not observed with NMN. PubMed
• Martens et al. 2018 (Nature Communications, n=24): 1,000mg NR daily for 6 weeks reduced aortic stiffness (a measure of cardiovascular aging) and systolic blood pressure (the top number in a blood pressure reading, reflecting pressure when the heart beats) in healthy middle-aged and older adults. PubMed
• Dollerup et al. 2018 (American Journal of Clinical Nutrition, n=40): 2,000mg NR daily for 12 weeks in obese, insulin-resistant men. Increased NAD+ metabolites in skeletal muscle but did not improve insulin sensitivity, mitochondrial function, or body composition. PubMed
• Conze et al. 2019 (Translational Medicine of Aging): Long-term safety study of NR at 100-1,000mg daily. Demonstrated dose-dependent NAD+ elevation and good tolerability. Funded by the patent holder. PubMed
• Elhassan et al. 2019 (Cell Reports, n=12): 1,000mg NR daily for 21 days in older adults increased NAD+ metabolome (the full set of NAD+ and related molecules in the body) in skeletal muscle and reduced circulating inflammatory cytokines (signaling proteins that promote inflammation). PubMed

Optimal Dose

NR lacks a proper multi-arm dose-response trial establishing a clear optimum. Most positive studies use 1,000mg/day. Based on the Cuenoud 2025 equivalence data with NMN, 500-600mg would be expected to produce similar NAD+ elevation to 600mg NMN, but this specific dose has not been independently validated in an RCT.

Side Effects

NR is generally well-tolerated. At higher doses (2,000mg/day), some studies have reported mild GI discomfort and occasional nausea. No serious adverse events in published trials.

Patent Status

This is where NR diverges sharply from NMN. NR is patent-restricted. One company holds over 90 patents covering NR composition, salt forms, synthesis methods, and use in combination products. Their original Dartmouth patent expired in April 2026, but newer patents extend effective IP protection for years beyond that.

For supplement brands, using NR means entering a licensing agreement with a single supplier -- including minimum order commitments and royalty structures. This cost is passed directly to consumers.

Regulatory Status

NR has had GRAS (Generally Recognized as Safe) status and an accepted NDIN since 2015, giving it a longer regulatory track record than NMN. However, this regulatory portfolio belongs to the patent holder, not the broader supplement industry.

Niacin Deep Dive (Including Niacinamide)

What It Is

Niacin is the collective term for two forms of vitamin B3 that feed into NAD+ production:

Nicotinic acid (NA) -- the original "niacin" -- enters the Preiss-Handler pathway. It has been used clinically since the 1950s, primarily for cholesterol management, and is the cheapest NAD+ precursor by a wide margin.

Nicotinamide (NAM, also called niacinamide) -- enters the salvage pathway via NAMPT, the same enzyme that recycles NAD+ breakdown products. It is the form typically found in B-complex vitamins and fortified foods.

These are distinct molecules with different metabolic fates, different side effect profiles, and a critical difference in how they interact with longevity-relevant enzymes.

How They Work

Nicotinic acid (NA): Converted to NaMN by the enzyme NAPRT (nicotinic acid phosphoribosyltransferase), then to NaAD by NMNAT, then to NAD+ by NAD synthetase. This three-step Preiss-Handler pathway is well-characterized and highly efficient when the enzymes are available. NA is also the molecule that gut bacteria produce when they metabolize NMN and NR -- making the Preiss-Handler pathway the common downstream route for all oral NAD+ precursors at the systemic level.

Nicotinamide (NAM): Converted to NMN by NAMPT, then to NAD+ by NMNAT. This is the same salvage pathway that NMN feeds into, but NAM enters one step earlier and requires NAMPT activity.

The Flushing Problem

Nicotinic acid causes a well-documented and often intense side effect: niacin flush. Within 15-30 minutes of ingesting 50mg or more, most people experience:

• Intense reddening of the face, neck, chest, and arms
• A burning, prickling sensation in the skin
• Warmth or heat across affected areas
• Occasionally, itching

This flush is caused by nicotinic acid activating the GPR109A receptor (also called HCA2 -- a receptor on immune cells in the skin) on Langerhans cells (immune cells in the skin). Activation triggers the release of prostaglandin D2 (PGD2) and prostaglandin E2 -- inflammatory lipid molecules that cause vasodilation (widening of blood vessels) in the skin.

The flush is not dangerous. It typically lasts 30-60 minutes and diminishes with repeated daily dosing as the body adapts. But it is profoundly uncomfortable for many people, and it's the primary reason niacin has never gained traction as a longevity supplement despite being effective, cheap, and well-studied.

Extended-release niacin formulations reduce flushing by slowing absorption, but they carry an increased risk of hepatotoxicity (liver damage) -- a serious tradeoff that led the FDA to withdraw approval of extended-release niacin/laropiprant combinations after the AIM-HIGH and HPS2-THRIVE trials showed no cardiovascular benefit and increased adverse events.

The Niacinamide Problem

Nicotinamide (niacinamide) does not cause flushing. It sounds like the perfect solution -- same vitamin B3 family, no flush, enters the salvage pathway. But at the doses needed for meaningful NAD+ elevation, niacinamide runs into a biological wall.

Nicotinamide is a sirtuin inhibitor. At concentrations above ~50 micromolar, nicotinamide directly inhibits sirtuin enzymes by occupying the enzyme's active site and preventing catalysis. This is a product inhibition mechanism (where the product of a reaction slows down the reaction itself) -- sirtuins produce nicotinamide when they consume NAD+, and that nicotinamide then inhibits further sirtuin activity.

At low dietary doses (the 15-20mg in food and multivitamins), this is irrelevant. At the hundreds of milligrams needed to meaningfully boost NAD+, nicotinamide's sirtuin-inhibitory effect becomes a serious concern. Sirtuins are central to many of the longevity benefits people take NAD+ precursors for in the first place -- activating them is half the point.

The Cuenoud 2025 study confirmed this concern in practice: plain nicotinamide produced only an acute 4-hour NAD+ spike but failed to sustain elevated NAD+ over 14 days, unlike NMN and NR which maintained approximately doubled NAD+ levels.

Clinical Evidence for Niacin

Niacin (nicotinic acid) has the longest clinical track record of any NAD+ precursor, though most research focused on its lipid-modifying effects rather than NAD+ elevation per se:

• Decades of lipid data: Niacin was a first-line cholesterol treatment from the 1960s through the 2000s. At 1,000-3,000mg/day, it raises HDL (high-density lipoprotein -- "good" cholesterol) by 15-35% and lowers LDL and triglycerides significantly. However, the AIM-HIGH (2011) and HPS2-THRIVE (2014) trials showed that adding niacin to statin therapy provided no additional cardiovascular benefit.
• Pirinen et al. 2020 (Cell Metabolism): 750-1,000mg niacin daily for 4 months in mitochondrial myopathy (a genetic disease affecting mitochondrial function in muscle) patients. NAD+ levels increased significantly in blood and muscle. Muscle strength and mitochondrial biogenesis (the process of creating new mitochondria) improved. This is the most relevant study for niacin as an NAD+ booster specifically. PubMed
• Elhassan et al. 2019 (Cell Reports): Used NR, but the study's metabolomics data showed that systemic NAD+ elevation from oral NAD+ precursors involves nicotinic acid as a downstream intermediate -- supporting the concept that the Preiss-Handler pathway is a common endpoint.

Optimal Dose

For NAD+ elevation specifically (not cholesterol management): 500-1,000mg/day of nicotinic acid, based on the Pirinen 2020 data. However, flushing makes this dose range intolerable for many people without a slow titration schedule (starting at 100mg and increasing by 100mg every few days).

For nicotinamide: there is no established optimal dose for NAD+ elevation because the sirtuin inhibition problem makes high-dose supplementation counterproductive for longevity purposes.

Safety Note: High-dose niacin (nicotinic acid) causes flushing in nearly all users and can elevate liver enzymes -- extended-release niacin carries increased hepatotoxicity risk. If you take statins, blood thinners, or diabetes medications, consult your physician before adding any NAD+ precursor. NMN and NR are well-tolerated but consume methyl groups; consider co-supplementing TMG.

Side Effects

Nicotinic acid: flushing (near-universal at effective doses), GI upset, and at high chronic doses, potential liver enzyme elevation. Extended-release formulations reduce flushing but increase hepatotoxicity risk.

Nicotinamide: generally well-tolerated but causes nausea at high doses (>3g/day) and inhibits sirtuins at concentrations relevant to NAD+ supplementation.

Cost

Niacin is extraordinarily cheap. A year's supply of nicotinic acid at 500mg/day costs approximately $5-15 retail. It is available as an over-the-counter supplement and as a prescription drug (for cholesterol management). No patents, no licensing, no special manufacturing required.

Tryptophan: The De Novo Pathway

What It Is

Tryptophan is an essential amino acid (one of nine that your body cannot make and must obtain from food) found in turkey, chicken, eggs, cheese, nuts, and seeds. It is best known as the precursor to serotonin (a neurotransmitter that regulates mood, sleep, and appetite) and melatonin (the hormone that regulates your sleep-wake cycle). Less well-known: it is also the starting material for NAD+ via the de novo (meaning "from scratch" -- the pathway that builds NAD+ from a non-vitamin starting material) synthesis pathway.

How It Works

The de novo pathway converts tryptophan to NAD+ through an eight-step process via the kynurenine pathway:

Tryptophan -> N-formylkynurenine -> kynurenine -> 3-hydroxykynurenine -> 3-hydroxyanthranilic acid -> aminocarboxymuconate semialdehyde -> quinolinic acid -> NaMN -> ... -> NAD+

The rate-limiting step is the initial conversion by either IDO (indoleamine 2,3-dioxygenase) or TDO (tryptophan 2,3-dioxygenase) enzymes. IDO is expressed in many tissues and is upregulated by inflammatory cytokines (meaning inflammation actually increases flux through this pathway, but much of the tryptophan gets diverted to neurotoxic intermediates rather than NAD+). TDO is primarily expressed in the liver.

The Efficiency Problem

The de novo pathway is profoundly inefficient for NAD+ production. The established conversion ratio is approximately 60:1 -- you need 60mg of dietary tryptophan to produce just 1mg of NAD+ equivalent (known as the "niacin equivalent" or NE).

To put this in perspective: to match the NAD+ production from 600mg of NMN, you would need tens of grams of tryptophan -- far more than is practical or safe from supplementation, and well beyond what you'd get from even a protein-heavy diet.

Why It Exists

If the de novo pathway is so inefficient, why does it matter? Because it is the only pathway that can build NAD+ from non-vitamin precursors. It is essential for baseline NAD+ homeostasis (the body's maintenance of stable internal NAD+ levels), especially in the liver, where TDO activity is high. It also serves as a "backup" system -- if you were completely deficient in all forms of vitamin B3, tryptophan from dietary protein would still allow your body to make NAD+ (preventing pellagra, the fatal disease of severe niacin deficiency).

However, for supplementation purposes -- actively boosting NAD+ levels above baseline -- the de novo pathway is essentially a non-starter. No one in the longevity community recommends tryptophan as an NAD+ booster, and for good reason.

Clinical Evidence

There are no human RCTs investigating tryptophan supplementation specifically for NAD+ elevation. Tryptophan supplementation research exists, but it focuses almost entirely on serotonin production, sleep quality, and mood -- not NAD+ metabolism.

Side Effects

Tryptophan at supplemental doses (500-2,000mg) can cause drowsiness (via serotonin and melatonin production), GI upset, and at very high doses, a risk of serotonin syndrome (a dangerous excess of serotonin activity, with symptoms including agitation, rapid heart rate, and fever) when combined with SSRIs or other serotonergic medications.

Practical Relevance

Near zero for NAD+ supplementation. Tryptophan is important for overall nutrition and serotonin/melatonin balance, but as an NAD+ precursor strategy, it is irrelevant compared to the other three options.

Key Takeaway: Niacin is the cheapest NAD+ precursor and raises NAD+ effectively through the Preiss-Handler pathway — but its flushing side effect (from prostaglandin release) limits practical dosing. Niacinamide avoids the flush but inhibits sirtuins at high doses (the opposite of what you want). Extended-release niacin reduces flushing but carries hepatotoxicity risk. These trade-offs are why NMN and NR have become the preferred precursors despite higher cost.

Head-to-Head Comparison Table

For a broader comparison of these NAD+ precursors alongside 25+ other longevity compounds ranked by evidence strength, see the Compound Index.

Cost Analysis

The economics of NAD+ precursors vary enormously. Here is what you can expect to pay at the time of writing (March 2026) for commonly available, reputable-quality products:

NMN (600mg/day):

• Branded (pharmaceutical-grade, >99% purity, CoA-verified): $40-60/month
• Generic (reputable manufacturer, third-party tested): $25-40/month
• Low-end (untested, no CoA): $15-25/month (not recommended -- purity and stability are critical for NMN due to its thermal sensitivity)

NR (1,000mg/day, patented formulation):

• Standard pricing: $40-80/month
• Limited options due to patent restrictions -- all products source from the same manufacturer
• No generic market exists

Niacin (500mg/day, nicotinic acid):

• $1-3/month
• This is not a typo. Niacin is one of the cheapest supplements on the planet. The tradeoff is the flushing.

Tryptophan (as NAD+ precursor):

• Not applicable. No effective dose exists for meaningful NAD+ elevation.

The cost-effectiveness calculation is straightforward: if you can tolerate the flush, niacin wins by a factor of 20x-50x. If you cannot (and most people cannot at effective doses for more than a few days), NMN offers the best combination of efficacy, cost, and tolerability.

For more on evaluating supplement quality and what to look for on a label, see How to Read a Supplement Label.

Key Takeaway: NMN leads the comparison: it has a dedicated intestinal transporter, requires one enzymatic step to become NAD+, showed superior NAD+ elevation in the 2025 head-to-head human trial, and has the best dose-response data (600mg optimal). NR is a solid second choice with better brand availability. Niacin is the budget option with meaningful trade-offs. Choose based on your priorities and budget.

Which Precursor for Which Goal?

Different goals may point toward different precursors:

Goal: Maximize NAD+ Levels for Longevity

Best choice: NMN at 600mg/day. It has the most precise dose-optimization data, no flushing, no sirtuin inhibition risk, no patent restrictions, and a growing body of human RCTs. NR is clinically equivalent for NAD+ elevation but costs more and involves single-supplier dependency.

Goal: Cheapest Possible NAD+ Boost

Best choice: Nicotinic acid (niacin) at 500-1,000mg/day. Requires tolerance of flushing during the first 1-2 weeks (which often diminishes with consistent daily dosing). Extended-release formulations reduce flushing but carry hepatotoxicity risk and are not recommended for unsupervised long-term use.

Goal: Support Gut Health While Boosting NAD+

Consider: NR. The Cuenoud 2025 study found NR uniquely increased gut SCFA production via Enterocloster aldensis. This is a single study and a secondary finding, but if gut microbiome health is a primary concern alongside NAD+ elevation, it is a legitimate data point.

Goal: General Nutrition (Not Targeted NAD+ Boosting)

Dietary niacin or tryptophan from food. If you are eating adequate protein and a balanced diet, you are already obtaining enough NAD+ precursors for baseline homeostasis. The RDA for niacin is just 16mg/day for men and 14mg/day for women. Supplementation becomes relevant when the goal is elevating NAD+ above baseline levels.

Goal: Cardiovascular Lipid Support

Prescription niacin (nicotinic acid) at 1,000-3,000mg/day. But only under medical supervision, and with the understanding that post-statin-era trials (AIM-HIGH, HPS2-THRIVE) showed no additive cardiovascular benefit when niacin was added to statin therapy.

The Tissue-Specificity Question

This is the most intellectually honest part of the NAD+ precursor conversation, and it is the part the supplement industry rarely discusses: different precursors may reach different tissues with different efficiencies.

What the Evidence Suggests

The Cuenoud 2025 study revealed that the majority of systemic NAD+ elevation from oral NMN and NR comes from a shared gut microbiome-mediated mechanism: bacteria convert both compounds to nicotinic acid, which enters the Preiss-Handler pathway in the liver. This explains the equivalence in circulating (blood) NAD+ levels.

But circulating NAD+ is not the whole story. NAD+ levels vary dramatically across tissues, and different tissues may preferentially use different pathways:

• Gut epithelium (the cells lining the intestinal wall): NMN may have a direct advantage here due to the SLC12A8 transporter, which directly imports intact NMN into intestinal cells without requiring gut bacterial conversion. NR uses nucleoside transporters (ENTs) for direct cellular uptake. The relative efficiency in gut tissue is not yet established in humans.
• Liver: The Preiss-Handler pathway is highly active in the liver, making niacin (nicotinic acid) potentially the most efficient precursor for hepatic (liver) NAD+ elevation. Since both NMN and NR are converted to NA by gut bacteria before reaching the liver, all three may be effectively equivalent for liver NAD+.
• Skeletal muscle: Elhassan 2019 showed NR increased NAD+ metabolome in skeletal muscle. The Pirinen 2020 study showed niacin increased muscle NAD+ and improved function in mitochondrial myopathy patients. NMN muscle data is more limited in humans.
• Brain: NAD+ precursor delivery to the brain is limited by the blood-brain barrier (a highly selective membrane that separates circulating blood from brain tissue, restricting which molecules can enter). NMN appears to cross the BBB in animal models via SLC12A8 (which is expressed in the hypothalamus), but human data is absent. NR may cross via ENTs. Nicotinic acid crosses poorly. This is an active area of research with no definitive human evidence.

What This Means Practically

The tissue-specificity question means that the "best" NAD+ precursor may eventually depend on where you most need NAD+ replenishment. For whole-blood NAD+ levels (the metric most commonly measured in clinical trials), NMN and NR are equivalent. For specific tissue targets, the answer may be more nuanced -- but the human evidence to make tissue-specific recommendations does not yet exist.

For now, this is a watching brief, not an actionable recommendation. It is worth being aware of, but it should not paralyze your decision-making. The evidence supports NMN at 600mg/day as the best-documented general approach.

For background on how NAD+ declines with age and why supplementation matters, that piece covers the foundational science.

Frequently Asked Questions

The Bottom Line: All four NAD+ precursors end up producing the same molecule, but NMN at 600mg/day offers the best combination of clinical evidence, tolerability, cost, and patent freedom for most people seeking sustained NAD+ restoration.

Related Reading

• What Is NMN? The Complete Guide to Nicotinamide Mononucleotide
• NMN vs NR: Which NAD+ Precursor Should You Take?
• NAD+ Decline by Age: The Complete Decade-by-Decade Timeline
• TMG: The Methylation Partner Your NMN Needs
• Sirtuins: The NAD+-Dependent Longevity Genes Your Body Already Has
• NAD+ and Gut Health: How NMN Reshapes Your Microbiome
• Bioavailability Explained: Why Supplement Form Matters More Than Dose

References:

1. Cuenoud B, et al. (2025). The differential impact of three different NAD+ boosters on circulatory NAD and microbial metabolism in humans. Nature Metabolism.
2. Yi L, et al. (2023). The efficacy and safety of NMN supplementation in healthy middle-aged adults. GeroScience, 45(1), 29-43.
3. Grozio A, et al. (2019). Slc12a8 is a nicotinamide mononucleotide transporter. Nature Metabolism, 1, 47-57.
4. Pirinen E, et al. (2020). Niacin cures systemic NAD+ deficiency and improves muscle performance in adult-onset mitochondrial myopathy. Cell Metabolism, 31(6), 1078-1090.
5. Martens CR, et al. (2018). Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nature Communications, 9(1), 1286.
6. Dollerup OL, et al. (2018). A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men. American Journal of Clinical Nutrition, 108(2), 343-353.
7. Elhassan YS, et al. (2019). Nicotinamide riboside augments the aged human skeletal muscle NAD+ metabolome and induces transcriptomic and anti-inflammatory signatures. Cell Reports, 28(7), 1717-1728.
8. Conze D, et al. (2019). Safety and metabolism of long-term administration of Niagen. Translational Medicine of Aging, 3, 43-52.
9. Liao B, et al. (2021). Nicotinamide mononucleotide supplementation enhances aerobic capacity in amateur runners. Journal of International Medical Research, 49(3).
10. Kim M, et al. (2022). Effect of 12-week intake of nicotinamide mononucleotide on sleep quality, fatigue, and physical performance in older Japanese adults. GeroScience.
11. Katayoshi T, et al. (2023). Nicotinamide mononucleotide: a promising molecule for therapy of diverse diseases by targeting NAD+ metabolism. Nutrients.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.